Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D.

Jason Lettmann被任命为首席执行官Dr。Jaume Pons过渡到加利福尼亚州南旧金山市首席科学官，2023年9月6日（GLOBE NEWSWIRE）-ALX Oncology Holdings Inc.，（“ALX Oncology”或“the Company”）（纳斯达克：ALXO），一家开发阻断CD47免疫检查点途径的治疗方法的免疫肿瘤公司，今天宣布董事会成员Jason Lettmann将继承Jaume Pons，博士。

as Chief Executive Officer, effective September 6, 2023. Dr. Pons will transition to the role of Chief Scientific Officer and remain President and both executives will remain members of the Board of Directors. “The realignment of our leadership team is a natural next step in the evolution the Company as our lead platform asset, evorpacept, advances to the later stages of clinical development with numerous datapoints across multiple indications in combination with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PDL-1 immune checkpoint inhibitors expected over the next 12 to 18 months,” commented Corey Goodman, Ph.D., Executive Chairman of ALX Oncology.

作为首席执行官，自2023年9月6日起生效。Pons博士将过渡到首席科学官的角色并担任总裁，两位高管仍将担任董事会成员。“我们领导团队的重组是公司发展的自然下一步-作为我们的领先平台资产evorpacept，通过多种适应症的众多数据点与抗癌抗体，抗体-药物结合物和PD-1/PDL-1免疫检查点抑制剂，预计将在未来12至18个月内实现。”评论了ALX肿瘤学执行主席Corey Goodman博士。

“As such, in collaboration with the Board and management team, Dr. Jaume Pons, our founder and the scientific inventor of evorpacept, will transition to the role of Chief Scientific Officer to focus on scientifically supporting evorpacept and pipeline extension programs and Jason Lettmann, a longstanding Board member with exceptional experience in the biotechnology industry, will assume the role of Chief Executive Officer.” Jason Lettmann has been involved with ALX Oncology for nearly a decade since its founding, having co-led the Company’s first institutional financing and serving as a member of the Company’s Board of Directors since 2015.

“因此，与董事会和管理团队合作，博士。我们的创始人兼evorpacept的科学发明者Jaume Pons将转变为首席科学官的角色，专注于科学支持evorpacept和管道扩展计划，而在生物技术行业拥有卓越经验的长期董事会成员Jason Lettmann将担任首席执行官的角色。”Jason Lettmann自成立以来已参与ALX肿瘤学近十年，自2015年以来共同领导该公司的第一次机构融资并担任该公司董事会成员。

Jason brings to the Chief Execu.

杰森带着首席执行官。